These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 17541428

  • 41. Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines.
    Sorolla A, Yeramian A, Dolcet X, Pérez de Santos AM, Llobet D, Schoenenberger JA, Casanova JM, Soria X, Egido R, Llombart A, Vilella R, Matias-Guiu X, Marti RM.
    Br J Dermatol; 2008 Mar; 158(3):496-504. PubMed ID: 18205878
    [Abstract] [Full Text] [Related]

  • 42. Mcl-1 is downregulated in cisplatin-induced apoptosis, and proteasome inhibitors restore Mcl-1 and promote survival in renal tubular epithelial cells.
    Yang C, Kaushal V, Shah SV, Kaushal GP.
    Am J Physiol Renal Physiol; 2007 Jun; 292(6):F1710-7. PubMed ID: 17311906
    [Abstract] [Full Text] [Related]

  • 43. Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse.
    Anan A, Baskin-Bey ES, Isomoto H, Mott JL, Bronk SF, Albrecht JH, Gores GJ.
    Am J Physiol Gastrointest Liver Physiol; 2006 Oct; 291(4):G709-16. PubMed ID: 16798723
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. BAG3 gene silencing sensitizes leukemic cells to Bortezomib-induced apoptosis.
    Liu P, Xu B, Li J, Lu H.
    FEBS Lett; 2009 Jan 22; 583(2):401-6. PubMed ID: 19111544
    [Abstract] [Full Text] [Related]

  • 47. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.
    Horton TM, Gannavarapu A, Blaney SM, D'Argenio DZ, Plon SE, Berg SL.
    Cancer Chemother Pharmacol; 2006 Jul 22; 58(1):13-23. PubMed ID: 16292537
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.
    Maseda D, Meister S, Neubert K, Herrmann M, Voll RE.
    Cell Death Differ; 2008 Mar 22; 15(3):600-12. PubMed ID: 18188168
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Combined RNA-expression and 2D-PAGE-screening identifies comprehensive interaction networks affected after bortezomib or enzastaurin exposure of mantle cell lymphoma.
    Weinkauf M, Hutter G, Zimmermann Y, Hartmann E, Rosenwald A, Dreyling M.
    Talanta; 2010 Feb 15; 80(4):1539-44. PubMed ID: 20082812
    [Abstract] [Full Text] [Related]

  • 52. MDA-7/IL-24, a novel tumor suppressor/cytokine is ubiquitinated and regulated by the ubiquitin-proteasome system, and inhibition of MDA-7/IL-24 degradation enhances the antitumor activity.
    Gopalan B, Shanker M, Scott A, Branch CD, Chada S, Ramesh R.
    Cancer Gene Ther; 2008 Jan 15; 15(1):1-8. PubMed ID: 17828282
    [Abstract] [Full Text] [Related]

  • 53. EGF receptor activity modulates apoptosis induced by inhibition of the proteasome of vascular smooth muscle cells.
    Ying WZ, Zhang HG, Sanders PW.
    J Am Soc Nephrol; 2007 Jan 15; 18(1):131-42. PubMed ID: 17151333
    [Abstract] [Full Text] [Related]

  • 54. Proteasome inhibitor bortezomib promotes a rupture-prone plaque phenotype in ApoE-deficient mice.
    Van Herck JL, De Meyer GR, Martinet W, Bult H, Vrints CJ, Herman AG.
    Basic Res Cardiol; 2010 Jan 15; 105(1):39-50. PubMed ID: 19693627
    [Abstract] [Full Text] [Related]

  • 55. Proteasome inhibition: mechanism of action.
    DeMartino GN.
    J Natl Compr Canc Netw; 2004 Nov 15; 2 Suppl 4():S5-9. PubMed ID: 19791423
    [Abstract] [Full Text] [Related]

  • 56. [Mechanism of bortezomib in inducing apoptosis and improving chemosensitivity of Ishikawa cells].
    Shen Y, Hu HY, Lu L.
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun 15; 30(6):1301-3, 1309. PubMed ID: 20584662
    [Abstract] [Full Text] [Related]

  • 57. Triggering of apoptosis by Puma is determined by the threshold set by prosurvival Bcl-2 family proteins.
    Callus BA, Moujallad DM, Silke J, Gerl R, Jabbour AM, Ekert PG, Vaux DL.
    J Mol Biol; 2008 Dec 12; 384(2):313-23. PubMed ID: 18835564
    [Abstract] [Full Text] [Related]

  • 58. Synergistic efficacy in human ovarian cancer cells by histone deacetylase inhibitor TSA and proteasome inhibitor PS-341.
    Fang Y, Hu Y, Wu P, Wang B, Tian Y, Xia X, Zhang Q, Chen T, Jiang X, Ma Q, Xu G, Wang S, Zhou J, Ma D, Meng L.
    Cancer Invest; 2011 May 12; 29(4):247-52. PubMed ID: 21345073
    [Abstract] [Full Text] [Related]

  • 59. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
    Zhao X, Qiu W, Kung J, Zhao X, Peng X, Yegappan M, Yen-Lieberman B, Hsi ED.
    Leuk Res; 2008 Feb 12; 32(2):275-85. PubMed ID: 17659339
    [Abstract] [Full Text] [Related]

  • 60. Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.
    Pekol T, Daniels JS, Labutti J, Parsons I, Nix D, Baronas E, Hsieh F, Gan LS, Miwa G.
    Drug Metab Dispos; 2005 Jun 12; 33(6):771-7. PubMed ID: 15764713
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.